Search

for
Search:

Research

5 / 1000+ results

A Case of Delusional Parasitosis Secondary to Severe Iron Deficiency Anemia in a Tertiary Care Hospital: An Area for Clinical Vigilance

research A Case of Delusional Parasitosis Secondary to Severe Iron Deficiency Anaemia in a Tertiary Care Hospital: An Area for Clinical Vigilance

June 2024 in “Journal of Psychiatry Spectrum”

This case report documented an elderly woman with delusional parasitosis, a belief of being infested by parasites, which was associated with severe anemia and resolved significantly after anemia treatment and antipsychotic medication.

research Real-world pharmacovigilance insights into drug-induced risk of alopecia

November 2025 in “Frontiers in Pharmacology”

This pharmacovigilance study identified 64 drugs linked to hair loss, revealing specific demographic trends and timing patterns, and emphasized the importance of gender-specific monitoring and label updates to better convey real-world risks.

research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases

October 2025 in “Frontiers in Medicine”

This study confirmed known adverse events and identified new ones related to ixekizumab, offering preliminary safety insights for its clinical use, but noted limitations such as potential underreporting and confounding factors in the spontaneous adverse event reporting systems.

Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

research Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel

3 citations , August 2023 in “Drug safety”

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

research Clinical management of patients withASXL1mutations and Bohring-Opitz syndrome, emphasizing the need for Wilms tumor surveillance

56 citations , April 2015 in “American journal of medical genetics. Part A”

This study reports on eight previously unpublished cases of Bohring-Opitz syndrome with ASXL1 mutations, suggesting the importance of screening for Wilms tumors in these patients.

View more "clinical vigilance" in research →

Community Join

5 / 1000+ results

community Finasteride does deplete important nuero-active steroids

11 upvotes 3 years ago

Finasteride can reduce neuroactive steroids, causing side effects like depression, anxiety, and sexual dysfunction. Some users experience persistent symptoms after stopping finasteride, while others use alternative treatments like topical solutions.

community Common hair-loss drug consistently associated with higher rates of psychiatric harm

in Research/Science 183 upvotes 11 months ago

Finasteride and dutasteride can cause psychiatric side effects like depression and suicidal thoughts in some users, especially those with a history of mental health issues. While some users experience positive hair growth results, others face severe psychological effects, raising concerns about their safety and the need for careful monitoring.

community Real world data from Europe shows that DUT is significantly safer than FIN in long term use

531 upvotes 1 year ago

Dutasteride is safer than finasteride for long-term use, with fewer sexual side effects. Users experience better hair regrowth and fewer side effects with dutasteride.

community "Clinical efficacy of microneedle combined with 5% Minoxidil solution and finasteride in the treatment of androgenetic alopecia in males"

in Research/Science 64 upvotes 1 year ago

Microneedling combined with 5% Minoxidil and finasteride significantly improves hair growth compared to using Minoxidil or Minoxidil with finasteride alone. The combination treatment is safe and effective, but further research is needed due to small sample size and short study duration.

community Clinical efficacy of popular oral supplements for AA

1 upvotes 5 years ago

Vitamins and minerals like vitamin E, zinc, and iron may aid hair growth, especially in cases of deficiency. Pumpkin seed oil, saw palmetto, horsetail, and AminoMar show some promise for improving hair health and count.

View more "clinical vigilance" in community →

Learn

5 / 801 results

learn KY19382

Are there clinical studies showing that KY19382 can regrow hair in androgenic alopecia? No clinical studies have proven KY19382 regrows hair in androgenic alopecia.

learn SCUBE3

What do clinical trials say about the safety and effectiveness of SCUBE3 for hair regrowth? No clinical trial of SCUBE3 for hair regrowth has been registered on ClinicalTrials.gov or published, so there is no human safety or effectiveness data. The evidence is limited to one 2022 laboratory and mouse study reporting that SCUBE3 activates hair follicle stem cells through TGF-beta signalling.

learn Follistatin

Are there any clinical studies supporting follistatin as a hair loss treatment? There is no controlled human trial showing follistatin treats hair loss; the published work is mouse and laboratory biology on the activin/follistatin signalling system, plus one small 2011 phase 1 injection study of a combination product, so follistatin remains experimental and unapproved.

learn Tofacitinib

What types of hair loss conditions are most commonly associated with tofacitinib use in clinical settings? Published studies link tofacitinib mainly to alopecia areata and its severe variants — as an off-label drug being studied for them, not as a cause of hair loss. The evidence is mostly small, open-label or retrospective, and relapse after stopping is commonly reported.

learn GT20029

When will GT20029 be commercially available, and are there any clinical trials on its use? GT20029 is not approved or commercially available anywhere and remains investigational. A published 12-week Phase II study in 180 Chinese men reports hair-count gains over placebo, but no long-term or Phase III data exists, so any launch is years away at best.

View more "clinical vigilance" in learn →

Clinics

6 / 500 results

All 500 clinic results →

Experts

— no results

Try a deeper search in experts →